Korean Circ J.  2023 Sep;53(9):650-651. 10.4070/kcj.2023.1991.

Author’s Reply to Cryptogenic Stroke, Patent Foramen Ovale Closure, and Mid to Long-term Outcomes: Rising Shadows of Doubt

• Lee OH
• Kim JS

• KMID: 2545961
• DOI: http://doi.org/10.4070/kcj.2023.1991

Reference

1. Dell’Angela L, Nicolosi GL. Cryptogenic stroke, patent foramen ovale closure, and mid to long-term outcomes: rising shadows of doubt. Korean Circ J. 2023; 53:648–649. PMID: 37653703.

2. Lee OH, Kim JS. Percutaneous patent foramen ovale closure after stroke. Korean Circ J. 2022; 52:801–807. PMID: 36347516.

3. Kolokathis K, Thomopoulos C, Tsioufis K. Net clinical benefit of PFO closure versus medical treatment in patients with cryptogenic stroke: a systematic review and meta-analysis. Hellenic J Cardiol. 2023; 70:46–52. PMID: 36584788.

4. Mojadidi MK, Elgendy AY, Elgendy IY, et al. Transcatheter patente foramen ovale closure after cryptogenic stroke: an updated meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017; 10:2228–2230. PMID: 29122137.

5. Staubach S, Steinberg DH, Zimmermann W, et al. New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv. 2009; 74:889–895. PMID: 19626689.

6. Skibsted CV, Korsholm K, Pedersen L, Bonnesen K, Nielsen-Kudsk JE, Schmidt M. Long-term risk of atrial fibrillation or flutter after transcatheter patent foramen ovale closure: a nationwide Danish study. Eur Heart J. 2023.

7. Trabattoni D, Gili S, Calligaris G, et al. Patent foramen ovale closure with the Occlutech Figulla flex II device: A long-term (up to 10-years) follow-up. Int J Cardiol. 2023.

8. Abrahamyan L, Barker M, Dharma C, et al. Real world long-term outcomes among adults undergoing transcatheter patent foramen closure with amplatzer PFO occluder. Int J Cardiol. 2023; 371:109–115. PMID: 36165815.